S&P 500   3,003.02 (+0.56%)
DOW   26,804.97 (+0.13%)
QQQ   193.09 (+0.73%)
AAPL   240.68 (+1.81%)
FB   189.04 (+1.72%)
MSFT   137.82 (+0.30%)
CGC   19.96 (-1.24%)
NVDA   195.95 (+2.87%)
BABA   172.33 (+1.89%)
GE   8.88 (-0.89%)
T   38.46 (-0.05%)
F   9.13 (-1.72%)
ACB   3.59 (-2.44%)
NFLX   275.20 (-0.04%)
BAC   31.02 (+2.17%)
GILD   65.20 (+0.45%)
DIS   131.04 (+0.11%)
S&P 500   3,003.02 (+0.56%)
DOW   26,804.97 (+0.13%)
QQQ   193.09 (+0.73%)
AAPL   240.68 (+1.81%)
FB   189.04 (+1.72%)
MSFT   137.82 (+0.30%)
CGC   19.96 (-1.24%)
NVDA   195.95 (+2.87%)
BABA   172.33 (+1.89%)
GE   8.88 (-0.89%)
T   38.46 (-0.05%)
F   9.13 (-1.72%)
ACB   3.59 (-2.44%)
NFLX   275.20 (-0.04%)
BAC   31.02 (+2.17%)
GILD   65.20 (+0.45%)
DIS   131.04 (+0.11%)
Log in

STARPHARMA HOLD/S Stock Price, News & Analysis (OTCMKTS:SPHRY)

$7.65
-0.45 (-5.56 %)
(As of 10/21/2019 09:00 AM ET)
Today's Range
$7.65
Now: $7.65
$7.65
50-Day Range
$7.42
MA: $7.81
$8.46
52-Week Range
$6.61
Now: $7.65
$11.87
Volume1,000 shs
Average Volume113 shs
Market Capitalization$284.35 million
P/E RatioN/A
Dividend YieldN/A
Beta1.5
Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company focuses on the development of VivaGel, which has completed Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for the prevention of sexually transmitted infections, as well as VivaGel condom, an antiviral condom. It also develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials for the treatment of a range of tumors, such as breast, prostate, and lung; and DEP cabazitaxel that is in Phase 1/2 clinical trial for solid tumors, as well as DEP irinotecan, an anti-cancer drug used to treat colorectal cancer. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:SPHRY
CUSIPN/A
CIKN/A
Phone61-3-8532-2700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.79 million
Book Value$1.11 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$284.35 million
Next Earnings DateN/A
OptionableNot Optionable

Receive SPHRY News and Ratings via Email

Sign-up to receive the latest news and ratings for SPHRY and its competitors with MarketBeat's FREE daily newsletter.


STARPHARMA HOLD/S (OTCMKTS:SPHRY) Frequently Asked Questions

What is STARPHARMA HOLD/S's stock symbol?

STARPHARMA HOLD/S trades on the OTCMKTS under the ticker symbol "SPHRY."

What is the consensus analysts' recommendation for STARPHARMA HOLD/S?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for STARPHARMA HOLD/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for STARPHARMA HOLD/S.

Has STARPHARMA HOLD/S been receiving favorable news coverage?

News coverage about SPHRY stock has been trending somewhat positive on Monday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. STARPHARMA HOLD/S earned a news impact score of 0.8 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for STARPHARMA HOLD/S.

Who are some of STARPHARMA HOLD/S's key competitors?

What other stocks do shareholders of STARPHARMA HOLD/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other STARPHARMA HOLD/S investors own include Starpharma (SPL) and AstraZeneca (AZN).

Who are STARPHARMA HOLD/S's key executives?

STARPHARMA HOLD/S's management team includes the folowing people:
  • Dr. Jacinth K. Fairley B.Sc., B.V.Sc.(Hons), MBA, GAICD, CEO, MD & Exec. Director (Age 56)
  • Mr. Nigel J. Baade, CFO & Company Sec.
  • Dr. A. Eglezos BSc(Hons), Ph.D., MBA, VP of Bus. Devel.
  • Dr. Jeremy R. Paull BSc (Hons), Ph.D., VP of Devel. & Regulatory Affairs
  • Dr. David J. Owen BSc(Hons) Ph.D., VP of Research

How do I buy shares of STARPHARMA HOLD/S?

Shares of SPHRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is STARPHARMA HOLD/S's stock price today?

One share of SPHRY stock can currently be purchased for approximately $7.65.

How big of a company is STARPHARMA HOLD/S?

STARPHARMA HOLD/S has a market capitalization of $284.35 million and generates $3.79 million in revenue each year. View Additional Information About STARPHARMA HOLD/S.

What is STARPHARMA HOLD/S's official website?

The official website for STARPHARMA HOLD/S is http://www.starpharma.com/.

How can I contact STARPHARMA HOLD/S?

STARPHARMA HOLD/S's mailing address is 4-6 Southampton Crescent, Abbotsford C3, 3072. The company can be reached via phone at 61-3-8532-2700 or via email at [email protected]


MarketBeat Community Rating for STARPHARMA HOLD/S (OTCMKTS SPHRY)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  22 (Vote Outperform)
Underperform Votes:  25 (Vote Underperform)
Total Votes:  47
MarketBeat's community ratings are surveys of what our community members think about STARPHARMA HOLD/S and other stocks. Vote "Outperform" if you believe SPHRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPHRY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Featured Article: Golden Cross

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel